Tandem Diabetes Care Inc Dossier
Qualitative Analysis
Business overview
Tandem Diabetes Care, Inc. is a global medical device company specializing in the design, development, and commercialization of advanced automated insulin delivery (AID) systems for people living with insulin-dependent diabetes. The company's flagship product portfolio includes the t:slim X2 insulin delivery system and the ultra-compact Tandem Mobi system, both powered by Control-IQ+ advanced hybrid closed-loop technology. Tandem is actively expanding its addressable market from type 1 diabetes to include adults with type 2 diabetes requiring intensive insulin therapy. The company is also executing a strategic transition in the United States toward a pharmacy-based, pay-as-you-go (PayGo) reimbursement model to improve patient access and establish predictable, recurring revenue streams.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning the U.S. commercial model to a pay-as-you-go (PayGo) pharmacy reimbursement structure, which features $0 upfront for pumps and ongoing reimbursement for supplies.
Expected impact: Expected to build a highly predictable, higher-margin recurring supplies revenue stream and accelerate long-term sales growth.
Transitioning from distributor-based models to direct commercial operations in key international markets.
Expected impact: Aims to average ~15% of international sales through direct operations, improving average selling prices (ASPs) by at least 30% in direct markets and enhancing pricing power.
Scaling the commercial footprint of Tandem Mobi, the world's smallest durable automated insulin delivery system, and expanding its interoperability.
Expected impact: Targets users valuing discretion and smartphone-centric control, complementing the t:slim X2 base and driving new-to-pump conversions.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire the Sigi Patch Pump technology, a reusable, rechargeable tubeless patch pump under development, to include a patch pump in Tandem's portfolio.
Financial impact: Upfront payment of CHF 62.4 million (plus CHF 8.0 million previous investment) with up to CHF 129.6 million in additional contingent earnout payments.
To acquire extended-wear infusion set technology (SteadiFlow/SteadiSet) to expand Tandem's portfolio of infusion sets and offer customers greater wear-time options.
Financial impact: Financial terms of the transaction were not disclosed.
To acquire a popular mobile app for people with diabetes to visualize therapy data, expanding Tandem's digital health ecosystem.
Financial impact: Financial terms of the transaction were not disclosed.
Strategic Partnerships
Enables integration of Tandem's t:slim X2, Mobi, and Sigi pumps with Dexcom's G6 and G7 continuous glucose monitoring (CGM) systems to drive automated insulin delivery.
Terms: Governed by an Amended and Restated Commercialization Agreement effective May 21, 2024.
Integrates Tandem's t:slim X2 pump with Abbott's FreeStyle Libre 3 Plus sensor in the U.S. (launched December 2025) and plans to connect with Abbott's upcoming glucose-ketone sensor.
Terms: Terms not publicly disclosed.